| ZFIN ID: ZDB-EXP-151228-10 |
Experiment Conditions Description: chemical treatment: rosiglitazone, chemical treatment: rimonabant
| chemical treatment: rosiglitazone |
|---|
| Name: | chemical treatment |
|---|---|
| Synonyms: | |
| Definition: | Experimental condition in which the fish is treated with a chemical substance. This treatment could be administered by adding the chemical substance to the tank water, injections, or by consumption. |
| Ontology: | Zebrafish Environment Condition Ontology [ZECO:0000111] |
| Name: | rosiglitazone |
|---|---|
| Synonyms: | 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione, 5-(4-{2-[methyl(pyridin-2-yl)amino]ethoxy}benzyl)-1,3-thiazolidine-2,4-dione, BRL-49653, rosiglitazona, rosiglitazone, rosiglitazonum |
| Definition: | |
| Ontology: | ChEBI [CHEBI:50122] ( EBI ) |
| chemical treatment: rimonabant |
|---|
| Name: | chemical treatment |
|---|---|
| Synonyms: | |
| Definition: | Experimental condition in which the fish is treated with a chemical substance. This treatment could be administered by adding the chemical substance to the tank water, injections, or by consumption. |
| Ontology: | Zebrafish Environment Condition Ontology [ZECO:0000111] |
| Name: | rimonabant |
|---|---|
| Synonyms: | 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide, A 281, Acomplia, N-(1-piperidinyl)-1-(2,4-dichlorophenyl)-4-methyl-5-(4-chlorophenyl)-1H-pyrazole-3-carboxamide, rimonabant, rimonabantum, SR 141716, SR141716, Zimulti |
| Definition: | A carbohydrazide obtained by formal condensation of the carboxy group of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid with the amino group of 1-aminopiperidine. It is a potent and selective cannabinoid receptor 1 (CB1R) antagonist. Besides its antagonistic properties, numerous studies have shown that, at micromolar concentrations rimonabant behaves as an inverse agonist at CB1 receptors. The drug was the first selective CB1 antagonist/inverse agonist introduced into clinical practice to treat obesity and metabolic-related disorders. It was later withdrawn from market due to CNS-related adverse effects including depression and suicidal ideation. |
| Ontology: | ChEBI [CHEBI:34967] ( EBI ) |
| Publication: | Fraher et al., 2015 |
|---|